A new study from Karyopharm Therapeutics Inc. suggests the company's exportin 1 (XPO1; CRM1) inhibitors could have therapeutic applications beyond cancer. The researchers found that blocking the nuclear export protein has neuroprotective and anti-inflammatory activity that could help treat multiple sclerosis (MS).
XPO1 transports proteins from the nucleus to the cytoplasm. In most cancers, high levels of XPO1 promote tumor cell survival by transporting tumor suppressor proteins and growth factors. Removing tumor suppressors from the nucleus prevents their anti-cancer activity, while transporting growth factors into the cytoplasm makes them available to promote cancer growth.